CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 15-28

  Meyer, Sara C ^a   Keller, Matthew D ^a   Chiu, Sophia ^a   Koppikar, Priya ^a   Guryanova, Olga A ^a   Rapaport, Franck ^a   Xu, Ke ^a   Manova, Katia ^a   Pankov, Dmitry ^a   O'Reilly, Richard J ^a   Kleppe, Maria ^a   McKenney, AnnaSophia ^a   Shih, Alan H ^a   Shank, Kaitlyn ^a   Ahn, Jihae ^a   Papalexi, Eftymia ^a   Spitzer, Barbara ^a   Socci, Nick ^a   Viale, Agnes ^a   Mandon, Emeline ^b   Ebel, Nicolas ^b   Andraos, Rita ^b   Rubert, Joëlle ^b   Dammassa, Ernesta ^b   Romanet, Vincent ^b   Dölemeyer, Arno ^b   Zender, Michael ^b   Heinlein, Melanie ^b   Rampal, Raajit ^a   Weinberg, RonaSinger ^c   Hoffman, Ronald ^d   Sellers, William R ^e   Hofmann, Francesco ^b   Murakami, Masato ^b   Baffert, Fabienne ^b   Gaul, Christoph ^b   Radimerski, Thomas ^b   Levine, RossL ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NEW YORK BLOOD CENTER   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHZ 868; FEDRATINIB; JANUS KINASE 2 INHIBITOR; MOMELOTINIB; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; RUXOLITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDERS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, THROMBOPOIETIN; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937426733     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.06.006     Document Type: Article

References (40)

1. Alcalá S., Klee M., Fernández J., Fleischer A., Pimentel-Muiños F.X. A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 2008, 27:44-54.
2. Andraos R., Qian Z., Bonenfant D., Rubert J., Vangrevelinghe E., Scheufler C., Marque F., Regnier C.H., De Pover A., Ryckelynck H., et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012, 2:512-523.
3. Argetsinger L.S., Kouadio J.L., Steen H., Stensballe A., Jensen O.N., Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 2004, 24:4955-4967.
4. Bandaranayake R.M., Ungureanu D., Shan Y., Shaw D.E., Silvennoinen O., Hubbard S.R. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 2012, 19:754-759.
5. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061. Cancer Genome Project.
6. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Hasselbalch H.C., Bowman R., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141-149.
7. Bhagwat N., Koppikar P., Keller M., Marubayashi S., Shank K., Rampal R., Qi J., Kleppe M., Patel H.J., Shah S.K., et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014, 123:2075-2083.
8. Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., McQuitty M., Hunter D.S., Levy R.S., Passamonti F., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013, 122:4047-4053. COMFORT-II investigators.
9. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
10. Deshpande A., Reddy M.M., Schade G.O., Ray A., Chowdary T.K., Griffin J.D., Sattler M. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012, 26:708-715.
11. Evrot E., Ebel N., Romanet V., Roelli C., Andraos R., Qian Z., Dolemeyer A., Dammassa E., Sterker D., Cozens R., et al. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin. Cancer Res. 2013, 19:6230-6241.
12. Fiskus W., Verstovsek S., Manshouri T., Smith J.E., Peth K., Abhyankar S., McGuirk J., Bhalla K.N. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol. Cancer Ther. 2013, 12:577-588.
13. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., McQuitty M., Hunter D.S., Levy R., Knoops L., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N.Engl. J. Med. 2012, 366:787-798.
14. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
15. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N.Engl. J. Med. 2013, 369:2379-2390.
16. Koppikar P., Abdel-Wahab O., Hedvat C., Marubayashi S., Patel J., Goel A., Kucine N., Gardner J.R., Combs A.P., Vaddi K., et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010, 115:2919-2927.
17. Koppikar P., Bhagwat N., Kilpivaara O., Manshouri T., Adli M., Hricik T., Liu F., Saunders L.M., Mullally A., Abdel-Wahab O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
18. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N.Engl. J. Med. 2005, 352:1779-1790.
19. Kubovcakova L., Lundberg P., Grisouard J., Hao-Shen H., Romanet V., Andraos R., Murakami M., Dirnhofer S., Wagner K.U., Radimerski T., Skoda R.C. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood 2013, 121:1188-1199.
20. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
21. Marubayashi S., Koppikar P., Taldone T., Abdel-Wahab O., West N., Bhagwat N., Caldas-Lopes E., Ross K.N., Gönen M., Gozman A., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J.Clin. Invest. 2010, 120:3578-3593.
22. Mullally A., Lane S.W., Ball B., Megerdichian C., Okabe R., Al-Shahrour F., Paktinat M., Haydu J.E., Housman E., Lord A.M., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
23. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N.Engl. J. Med. 2013, 369:2391-2405.
24. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
25. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3:e270.
26. Pronk C.J., Rossi D.J., Månsson R., Attema J.L., Norddahl G.L., Chan C.K., Sigvardsson M., Weissman I.L., Bryder D. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 2007, 1:428-442.
27. Rampal R., Al-Shahrour F., Abdel-Wahab O., Patel J.P., Brunel J.P., Mermel C.H., Bass A.J., Pretz J., Ahn J., Hricik T., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014, 123:e123-e133.
28. Schuringa J.J., Wu K., Morrone G., Moore M.A. Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis invivo. Stem Cells 2004, 22:1191-1204.
29. Schwaab J., Ernst T., Erben P., Rinke J., Schnittger S., Ströbel P., Metzgeroth G., Mossner M., Haferlach T., Cross N.C., et al. Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Ann. Hematol. 2012, 91:1713-1720.
30. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N.Engl. J. Med. 2007, 356:459-468.
31. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105:4604-4612.
32. Tyner J.W., Bumm T.G., Deininger J., Wood L., Aichberger K.J., Loriaux M.M., Druker B.J., Burns C.J., Fantino E., Deininger M.W. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010, 115:5232-5240.
33. Ungureanu D., Wu J., Pekkala T., Niranjan Y., Young C., Jensen O.N., Xu C.F., Neubert T.A., Skoda R.C., Hubbard S.R., Silvennoinen O. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 2011, 18:971-976.
34. Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., Barosi G., Ruggeri M., Specchia G., Lo-Coco F., Delaini F., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112:844-847.
35. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., Catalano J.V., Deininger M., Miller C., Silver R.T., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N.Engl. J. Med. 2012, 366:799-807.
36. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., Catalano J.V., Deininger M.W., Miller C.B., Silver R.T., et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98:1865-1871.
37. Weigert O., Lane A.A., Bird L., Kopp N., Chapuy B., van Bodegom D., Toms A.V., Marubayashi S., Christie A.L., McKeown M., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J.Exp. Med. 2012, 209:259-273.
38. Wu S.-C., Li L.S., Kopp N., Montero J., Chapuy B., Yoda A., Christie A.L., Liu H., Christodoulou A., van Bodegom D., et al. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell 2015, 28:29-41. this issue.
39. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J.Biol. Chem. 2005, 280:22788-22792.
40. Zhu Z., Aref A.R., Cohoon T.J., Barbie T.U., Imamura Y., Yang S., Moody S.E., Shen R.R., Schinzel A.C., Thai T.C., et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014, 4:452-465.